At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 101 enrolled
Drug / intervention
Levothyroxine sodium new formulationdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Open-label Switch Study to Investigate the Necessity of Dose Adjustment After Switching From L-Thyroxine Christiaens® to the New Levothyroxine Sodium Test Formulation in (Near) Total Thyroidectomised Patients.
In Brief
A Phase 2 clinical trial evaluating Levothyroxine sodium new formulation for Hypothyroidism. Completed, enrolled 101 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the effect of switching participants taking levothyroxine to a new sodium formulation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypothyroidism
CountriesBelgium
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedAug 2013
Primary CompletionJun 2014
TodayJul 2026
First PostedAug 5, 2013
Enrollment StartJul 1, 2013
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.9 years ago
Interventions
Levothyroxine sodium new formulationdrug
Levothyroxine tablets